v3.26.3
Consolidated Statements of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Total Teva shareholders' equity
Ordinary shares
Additional paid-in capital
Retained earnings (accumulated deficit)
Accumulated other comprehensive income (loss)
Treasury shares
Non-controlling interests
Beginning balance (in shares) at Dec. 31, 2024     1,240          
Beginning balance at Dec. 31, 2024 $ 5,380 $ 5,373 $ 58 $ 27,764 $ (15,173) $ (3,148) $ (4,128) $ 7
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) 937              
Net income (loss), including portion attributable to noncontrolling interest and mezzanine Items 931 930     930     1
Other comprehensive income (loss) 673 673       673    
Issuance of Shares (in shares)     13          
Issuance of shares [1] [1]        
Stock-based compensation expense 106 106   106        
Proceeds from exercise of options 3 3   3        
Purchase of shares from redeemable non-controlling interests [2] 165 165   165        
Dividend to non-controlling interest [3] (4)             (4)
Ending balance (in shares) at Sep. 30, 2025     1,253          
Ending balance at Sep. 30, 2025 7,254 7,250 $ 58 28,038 (14,243) (2,475) (4,128) 4
Beginning balance (in shares) at Jun. 30, 2025     1,253          
Beginning balance at Jun. 30, 2025 6,834 6,827 $ 58 28,003 (14,676) (2,431) (4,128) 7
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) 434 433     433      
Other comprehensive income (loss) (44) (44)       (44)    
Stock-based compensation expense 34 34   34        
Ending balance (in shares) at Sep. 30, 2025     1,253          
Ending balance at Sep. 30, 2025 7,254 7,250 $ 58 28,038 (14,243) (2,475) (4,128) 4
Beginning balance (in shares) at Dec. 31, 2025     1,257          
Beginning balance at Dec. 31, 2025 7,914 7,910 $ 58 28,133 (13,762) (2,391) (4,128) 4
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) 27 26     26     1
Other comprehensive income (loss) (164) (165)       (165)   1
Issuance of Shares (in shares)     15          
Issuance of shares [1] [1]        
Stock-based compensation expense 121 121   121        
Proceeds from exercise of options 85 85   85        
Reissuance of treasury shares for stock compensation plans 0 0   (31)     31  
Ending balance (in shares) at Sep. 30, 2026     1,272          
Ending balance at Sep. 30, 2026 7,984 7,979 $ 59 28,309 (13,736) (2,556) (4,097) 5
Beginning balance (in shares) at Jun. 30, 2026     1,271          
Beginning balance at Jun. 30, 2026 7,757 7,753 $ 59 28,256 (13,969) (2,465) (4,128) 4
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income (loss) 234 233     233     1
Other comprehensive income (loss) (90) (91)       (91)   1
Issuance of Shares (in shares) [1]              
Issuance of shares [1] [1]        
Stock-based compensation expense 38 38   38        
Proceeds from exercise of options 46 46   46        
Reissuance of treasury shares for stock compensation plans 0 0   (31)     31  
Dividend to non-controlling interest [3] (4)             (4)
Ending balance (in shares) at Sep. 30, 2026     1,272          
Ending balance at Sep. 30, 2026 $ 7,984 $ 7,979 $ 59 $ 28,309 $ (13,736) $ (2,556) $ (4,097) $ 5
[1]
Represents an amount less than $0.5 million.
[2] In connection with the sale of Teva’s business venture in Japan.
[3] In connection with a declaration of dividends to non-controlling interests in Teva’s subsidiary in Bulgaria.